接受调强放射治疗的鼻咽癌患者的长期晚期毒性、生活质量及情绪困扰
这项横断面队列研究纳入107例无病生存且调强放射治疗后≥4年的鼻咽癌患者,中位年龄57岁,中位治疗至入组时间7.5年。99%接受70 Gy/35次,93%接受同步化疗。医生报告≥3级不良事件47%,听力问题最常见(43%);听力检查示72%有显著双侧听力损失(≥3级);抑郁25%、焦虑37%、疲乏28%常见且与生活质量强相关;69%发生甲状腺功能减退,甲状腺V50>90和V45>99与更高甲减率相关。结论认为即使采用调强放射治疗,长期存活者仍存在多种影响生活质量的躯体症状。
要点
- 中位随访7.5年时,47%患者有医生报告≥3级不良事件,听力问题最常见(43%)。
- 听力检查示72%患者有显著双侧听力损失(≥3级),69%发生甲状腺功能减退。
- 抑郁25%、焦虑37%、疲乏28%常见且与生活质量强相关。
核心结论
- 尽管实施了调强放射治疗,鼻咽癌存活者在治疗后多年仍经历许多影响长期生活质量的躯体症状。
- 抑郁、焦虑和疲乏在长期存活者中仍然常见,且与生活质量高度相关。
研究设计与样本
- 横断面队列研究,纳入无病生存且调强放射治疗±化疗后≥4年的鼻咽癌患者,来自非流行区中心。
- 共纳入107例患者,入组时中位年龄57岁(范围32-81),距治疗中位时间7.5年(范围4.2-11.1)。
- 收集医生报告的不良事件(常见不良事件评价标准第4.03版)、患者报告的生活质量(癌症治疗功能评价-头颈、慢性病治疗功能评价-疲乏)、效用(EuroQOL-5D)、头颈症状(MD安德森症状量表-头颈)及情绪困扰(医院焦虑抑郁量表);同意者接受内分泌筛查和听力检查。
主要发现
- 99%患者接受70 Gy/35次,93%接受同步化疗。
- 癌症治疗功能评价-头颈、慢性病治疗功能评价-疲乏和EuroQOL-5D的平均分分别为105.0(范围46-148)、116.6(范围44-160)和0.85(范围0.29-1.00)。
- MD安德森症状量表-头颈中评分最高的症状为口干、黏液、吞咽/咀嚼、记忆和牙齿/牙龈问题;平均症状严重程度和症状干扰评分分别为2.3和2.4。
- 50例(47%)有医生报告≥3级不良事件,最常见为听力问题(46例,43%);听力检查示68例(72%)有显著双侧听力损失(≥3级)。
- 抑郁(25%)、焦虑(37%)和疲乏(28%)常见且与生活质量强相关;大多数患者(69%)发生甲状腺功能减退,1例(1%)发生需激素替代的垂体功能障碍;甲状腺V50>90和V45>99与显著更高的甲状腺功能减退率相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report long-term (>4 years) toxicity and quality of life (QoL) among patients with nasopharyngeal carcinoma (NPC) treated with intensity modulated radiation therapy (IMRT) in a nonendemic center. METHODS AND MATERIALS: A cross-sectional cohort study enrolled patients with NPC who were disease-free and ≥4 years after IMRT ± chemotherapy. Physician-reported adverse events (Common Terminology Criteria for Adverse Events, version 4.03) and patient-reported QoL (Functional Assessment of Cancer Therapy-Head and Neck, Functional Assessment of Chronic Illness Therapy-Fatigue), utilities (EuroQOL-5D), head and neck symptoms (MD Anderson Symptom Inventory-Head and Neck), and emotional distress (Hospital Anxiety and Depression Scale) were collected. Consenting patients also underwent endocrine screening and audiometry. RESULTS: Among 107 patients enrolled, median age at enrollment and time since treatment were 57 (32-81) and 7.5 years (4.2-11.1), respectively. Most patients (99%) received 70 Gy in 35 fractions; the majority (93%) received concurrent chemotherapy. Mean scores for the Functional Assessment of Cancer Therapy-Head and Neck, Functional Assessment of Chronic Illness Therapy-Fatigue, and EuroQOL-5D were 105.0 (46-148), 116.6 (44-160), and 0.85 (0.29-1.00), respectively. Dry mouth, mucus, swallowing/chewing, memory, and teeth/gum problems were scored highest on the MD Anderson Symptom Inventory-Head and Neck; mean symptom severity and symptom interference scores were 2.3 and 2.4, respectively. Grade 3 or higher physician-reported adverse events were noted in 50 patients (47%), most frequently hearing problems (46, 43%). Audiometry revealed significant bilateral hearing loss (grade ≥3) in 68 patients (72%). Depression (25%), anxiety (37%), and fatigue (28%) were common and strongly correlated with QoL. Most patients (69%) developed hypothyroidism; 1 patient (1%) developed pituitary dysfunction requiring hormone replacement. V50 >90 and V45 >99 to the thyroid correlated with significantly higher rates of hypothyroidism. CONCLUSIONS: Despite the implementation of IMRT, survivors of NPC still experience many physical symptoms that affect long-term QoL many years after treatment. Depression, anxiety, and fatigue remain common in long-term survivors and are highly correlated with QoL.
引用
- McDowell LJ, Rock K, Xu W, et al. Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30191868. doi:10.1016/j.ijrobp.2018.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。